Zimmer Biomet Holdings, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 6.83B | 6.94B | 7.39B | 7.68B | 8.23B | 7.2% | |
| Cost of Revenue | (1.96B) | (2.02B) | (2.08B) | (2.19B) | (3.16B) | 44.2% | |
Gross Profit | 4.87B | 4.92B | 5.31B | 5.49B | 5.07B | -7.6% | |
| Operating Expenses | |||||||
| Research & Development | (435.80M) | (406.00M) | (458.70M) | (437.40M) | (458.50M) | 4.8% | |
| Selling, General & Administrative | (2.84B) | (2.76B) | (2.84B) | (2.93B) | (3.25B) | 11.0% | |
| Depreciation & Amortization | (937.70M) | (926.40M) | (951.70M) | (996.30M) | (1.09B) | 9.8% | |
Operating Income (EBIT) | 860.30M | 696.30M | 1.28B | 1.29B | 1.36B | 6.0% | |
| Non-Operating Items | |||||||
| Interest Income | — | — | — | — | — | — | |
| Interest Expense | (208.40M) | (164.80M) | (201.20M) | (218.00M) | (292.80M) | 34.3% | |
| Other Income/Expenses (Net) | -361.30M | -292.80M | -210.40M | -249.10M | -531.40M | 113.3% | |
Income Before Tax | 499.00M | 403.50M | 1.07B | 1.04B | 830.80M | -19.9% | |
| Income Tax Expense | (53.50M) | (112.30M) | (42.20M) | (131.40M) | (125.70M) | -4.3% | |
Net Income | 401.60M | 231.40M | 1.02B | 903.80M | 705.20M | -22.0% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $2 | $1 | $5 | $4 | $4 | -20.0% | |
| Weighted Avg Shares Outstanding | 208.60M | 209.60M | 208.70M | 203.10M | 198.00M | -2.5% | |
| Weighted Avg Shares Outstanding (Diluted) | 210.40M | 210.30M | 209.70M | 203.90M | 198.70M | -2.6% | |
EBITDA | 1.65B | 1.49B | 2.22B | 2.25B | 2.22B | -1.5% |
Explore ZBH
ZBH in the Healthcare
Large Cap